Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease--a randomized, multicenter, double-blind, placebo-controlled study.

COPD: the patient perspective. Int J Chron Obstruct Pulmon Dis (2016) 0.81

Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design. BMJ Open (2016) 0.79

Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study). BMC Pulm Med (2016) 0.78

Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2015) 0.77

Effects of pharmacologic treatment based on airflow limitation and breathlessness on daily physical activity in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2015) 0.77

Differences in physical activity according to mMRC grade in patients with COPD. Int J Chron Obstruct Pulmon Dis (2016) 0.76

Validity and Usability of Physical Activity Monitoring in Patients with Chronic Obstructive Pulmonary Disease (COPD). PLoS One (2016) 0.75

Exercise training alone or with the addition of activity counseling improves physical activity levels in COPD: a systematic review and meta-analysis of randomized controlled trials. Int J Chron Obstruct Pulmon Dis (2016) 0.75

Effect of Indacaterol on Cough and Phlegm in Chronic Obstructive Pulmonary Disease Patients: A Meta-Analysis of Five Randomized Controlled Trials. J Korean Med Sci (2015) 0.75

Standardisation of spirometry. Eur Respir J (2005) 48.20

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96

Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. Public Health Rep (1985) 10.50

Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet (2011) 9.49

Standardisation of the measurement of lung volumes. Eur Respir J (2005) 7.48

Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax (2006) 4.04

Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax (2003) 4.02

Physical activity in patients with COPD. Eur Respir J (2008) 3.75

Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest (2011) 3.72

Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J (2004) 3.19

Minimal clinically important differences in COPD lung function. COPD (2005) 3.00

Physical activity and hospitalization for exacerbation of COPD. Chest (2006) 2.24

Body plethysmography--its principles and clinical use. Respir Med (2011) 2.15

Physical inactivity in patients with COPD, a controlled multi-center pilot-study. Respir Med (2010) 2.06

Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest (2003) 1.90

Validity of six activity monitors in chronic obstructive pulmonary disease: a comparison with indirect calorimetry. PLoS One (2012) 1.77

Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. Respir Med (2011) 1.61

Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc (2006) 1.56

Quadriceps wasting and physical inactivity in patients with COPD. Eur Respir J (2012) 1.52

Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with dynamic hyperinflation. Am J Respir Crit Care Med (2009) 1.41

Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med (2011) 1.41

Dyspnea and activity limitation in COPD: mechanical factors. COPD (2007) 1.23

Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med (2011) 1.23

Measurement properties of the SenseWear armband in adults with chronic obstructive pulmonary disease. Thorax (2010) 1.20

Improving physical activity in COPD: towards a new paradigm. Respir Res (2013) 1.20

Why does the lung hyperinflate? Proc Am Thorac Soc (2006) 1.17

Prognostic value of the objective measurement of daily physical activity in patients with COPD. Chest (2012) 1.17

Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD (2011) 1.01

Consequences of physical inactivity in chronic obstructive pulmonary disease. Expert Rev Respir Med (2010) 0.98

Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2012) 0.95

Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials. BMC Pulm Med (2013) 0.94

Assessing the Impact of Tiotropium on Lung Function and Physical Activity in GOLD Stage II COPD Patients who are Naïve to Maintenance Respiratory Therapy: A Study Protocol. Open Respir Med J (2011) 0.91

Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium. Respir Res (2012) 0.87

Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol. Int J Chron Obstruct Pulmon Dis (2011) 0.84

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96

Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med (2014) 6.29

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 4.82

An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest (2003) 3.19

Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit Care Med (2007) 2.93

FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J (2013) 2.87

Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax (2010) 2.79

The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest (2009) 2.21

Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest (2010) 2.02

Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest (2006) 1.84

CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med (2015) 1.70

Assessment of lymph node tuberculosis in northern Germany: a clinical review. Chest (2002) 1.66

Responses to bronchial challenge submitted for approval to use inhaled beta2-agonists before an event at the 2002 Winter Olympics. J Allergy Clin Immunol (2003) 1.65

An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63

Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 1.63

Lung fibroblast repair functions in patients with chronic obstructive pulmonary disease are altered by multiple mechanisms. Am J Respir Crit Care Med (2008) 1.50

Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. Respiration (2006) 1.45

Comparison of two devices and two breathing patterns for exhaled breath condensate sampling. PLoS One (2011) 1.45

Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest (2011) 1.40

Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med (2007) 1.35

Passive smoking exposure: a risk factor for chronic bronchitis and asthma in adults? Chest (2002) 1.34

Reduced miR-146a increases prostaglandin E₂in chronic obstructive pulmonary disease fibroblasts. Am J Respir Crit Care Med (2010) 1.33

TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers (2005) 1.32

Allergic airway inflammation inhibits pulmonary antibacterial host defense. J Immunol (2006) 1.31

Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir Res (2010) 1.31

Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther (2010) 1.30

The discovery of α1-antitrypsin and its role in health and disease. Respir Med (2011) 1.30

Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med (2011) 1.23

Peripheral arterial tonometry, oximetry and actigraphy for ambulatory recording of sleep apnea. Physiol Meas (2004) 1.22

Microbial DNA induces a host defense reaction of human respiratory epithelial cells. J Immunol (2004) 1.18

Association of depression and anxiety with health care use and quality of life in asthma patients. Respir Med (2006) 1.13

The anti-microbial peptide LL-37 inhibits the activation of dendritic cells by TLR ligands. Int Immunol (2006) 1.13

The antimicrobial peptide LL-37 modulates the inflammatory and host defense response of human neutrophils. Eur J Immunol (2010) 1.12

Seasonal distribution of COPD exacerbations in the Prevention of Exacerbations with Tiotropium in COPD trial. Chest (2013) 1.09

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res (2011) 1.09

Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol (2005) 1.07

Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. COPD (2010) 1.06

Association of tumor necrosis factor-alpha polymorphisms and ozone-induced change in lung function. Am J Respir Crit Care Med (2004) 1.05

Guideline-based survey of outpatient COPD management by pulmonary specialists in Germany. Int J Chron Obstruct Pulmon Dis (2012) 1.04

Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity. PLoS One (2012) 1.03

Chronic obstructive pulmonary disease and premature aging. Am J Respir Crit Care Med (2007) 1.02

Airway response to emotional stimuli in asthma: the role of the cholinergic pathway. J Appl Physiol (1985) (2010) 1.02

Dynamics of heart rate and sleep stages in normals and patients with sleep apnea. Neuropsychopharmacology (2003) 1.02

Exposure of differentiated airway epithelial cells to volatile smoke in vitro. Respiration (2004) 1.00

Nonrandom variability of respiration during sleep in healthy humans. Sleep (2005) 1.00

Stress effects on lung function in asthma are mediated by changes in airway inflammation. Psychosom Med (2008) 0.98

Intervention by phone calls raises domiciliary activity and exercise capacity in patients with severe COPD. Respir Med (2007) 0.95

Development and validation of a cough and sputum assessment questionnaire. Respir Med (2008) 0.95

Comparison of exhaled breath condensate pH using two commercially available devices in healthy controls, asthma and COPD patients. Respir Res (2009) 0.94

PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol (2009) 0.94

Whole-body vibration therapy in intensive care patients: A feasibility and safety study. J Rehabil Med (2016) 0.94

Validation of the human ozone challenge model as a tool for assessing anti-inflammatory drugs in early development. J Clin Pharmacol (2005) 0.94

Identification of individuals with alpha-1-antitrypsin deficiency by a targeted screening program. Respir Med (2007) 0.93

Opportunities and challenges in the genetics of COPD 2010: an International COPD Genetics Conference report. COPD (2011) 0.93

Prostacyclin analogs stimulate VEGF production from human lung fibroblasts in culture. Am J Physiol Lung Cell Mol Physiol (2008) 0.91

Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study. Respir Res (2009) 0.91

Verbal descriptors of dyspnea in patients with COPD at different intensity levels of dyspnea. Chest (2007) 0.89

Perceived triggers of asthma: evaluation of a German version of the Asthma Trigger Inventory. Respir Med (2007) 0.89

Acute and chronic effects of smoking on inflammation markers in exhaled breath condensate in current smokers. Respiration (2009) 0.88

Alpha-1 antitrypsin is elevated in exhaled breath condensate and serum in exacerbated COPD patients. Respir Med (2011) 0.88

Diagnostic outcome of two different CT-guided fine needle biopsy procedures. Diagn Pathol (2007) 0.87

Association between obesity and atopy in adults? Int Arch Allergy Immunol (2011) 0.87

Inhibition of NF-kappaB mediated inflammation by siRNA expressed by recombinant adeno-associated virus. J Virol Methods (2004) 0.86

Efficacy of indacaterol in the treatment of patients with COPD. Prim Care Respir J (2011) 0.86

The impact of affective states on the perception of dyspnea in patients with chronic obstructive pulmonary disease. Biol Psychol (2009) 0.86

Effects of 3-week outpatient pulmonary rehabilitation on exercise capacity, dyspnea, and quality of life in COPD. Lung (2008) 0.85

Alpha1-antitrypsin deficiency - diagnostic testing and disease awareness in Germany and Italy. Respir Med (2013) 0.85

Discrimination between COPD patients with and without alpha 1-antitrypsin deficiency using an electronic nose. Respirology (2011) 0.85

Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. Orphanet J Rare Dis (2013) 0.85

Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. Int J Chron Obstruct Pulmon Dis (2009) 0.84

Ambient temperature impacts on pH of exhaled breath condensate. Respirology (2009) 0.84

Episodic breathlessness in patients with advanced disease: a systematic review. J Pain Symptom Manage (2012) 0.84

Benefits of whole body vibration training in patients hospitalised for COPD exacerbations - a randomized clinical trial. BMC Pulm Med (2014) 0.83

Efficacy of the pan-selectin antagonist Bimosiamose on ozone-induced airway inflammation in healthy subjects--a double blind, randomized, placebo-controlled, cross-over clinical trial. Pulm Pharmacol Ther (2011) 0.83

Exercise training raises daily activity stronger than predicted from exercise capacity in patients with COPD. Respir Med (2005) 0.83

Oncostatin M modulates fibroblast function via signal transducers and activators of transcription proteins-3. Am J Respir Cell Mol Biol (2013) 0.82

Impact of different definitions of airflow limitation on the prevalence of chronic obstructive pulmonary disease in the general population. Respiration (2010) 0.82

Imatinib-associated pulmonary alveolar proteinosis. Am J Med (2003) 0.82

Anti-inflammatory effects of budesonide in human lung fibroblast are independent of histone deacetylase 2. J Inflamm Res (2013) 0.81

The EvA study: aims and strategy. Eur Respir J (2012) 0.81

HOPE-preservation of paraffin-embedded sputum samples--a new way of bioprofiling in COPD. Respir Med (2013) 0.81

Cell-specific modulation of surfactant proteins by ambroxol treatment. Toxicol Appl Pharmacol (2005) 0.81

Distractive auditory stimuli reduce the unpleasantness of dyspnea during exercise in patients with COPD. Chest (2007) 0.81

Psychological triggers and hyperventilation symptoms in asthma. Ann Allergy Asthma Immunol (2008) 0.81

Krüppel-like zinc finger proteins in end-stage COPD lungs with and without severe alpha1-antitrypsin deficiency. Orphanet J Rare Dis (2012) 0.80

Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe. Respir Med (2012) 0.80

Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma. Pharmacoeconomics (2005) 0.79

Cognitive biases in patients with chronic obstructive pulmonary disease and depression--a pilot study. Br J Health Psychol (2013) 0.79

Effect of azelastine, montelukast, and their combination on allergen-induced bronchoconstriction in asthma. Pulm Pharmacol Ther (2006) 0.79

Tracheostomy and related host-pathogen interaction are associated with airway inflammation as characterized by tracheal aspirate analysis. Respir Med (2008) 0.79

Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease. Ther Adv Respir Dis (2011) 0.78

Emphysema, airflow obstruction, and left ventricular filling. N Engl J Med (2010) 0.78

Regional differences in prediction models of lung function in Germany. Respir Res (2010) 0.78

Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD. Respir Med (2010) 0.78

Cutoff values for FENO-guided asthma management. Am J Respir Crit Care Med (2009) 0.78

Prediction of new-onset asthma and nasal allergy by skin prick test and RAST in a cohort of adults. Eur Respir J (2013) 0.78

[Budesonide/formoterol maintenance and reliever therapy. A new treatment approach for adult patients with asthma]. Med Klin (Munich) (2008) 0.78